- Home
- VRCA vs CTSO Comparison
VRCA vs CTSO Comparison
Compare VRCA & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- CTSO
- Stock Information
- Founded
- VRCA 2013
- CTSO 1997
- Country
- VRCA United States
- CTSO United States
- Employees
- VRCA N/A
- CTSO N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- CTSO Medical/Dental Instruments
- Sector
- VRCA Health Care
- CTSO Health Care
- Exchange
- VRCA Nasdaq
- CTSO Nasdaq
- Market Cap
- VRCA 58.0M
- CTSO 51.6M
- IPO Year
- VRCA 2018
- CTSO N/A
- Fundamental
- Price
- VRCA $0.72
- CTSO $0.99
- Analyst Decision
- VRCA Hold
- CTSO Strong Buy
- Analyst Count
- VRCA 5
- CTSO 3
- Target Price
- VRCA $6.00
- CTSO $4.67
- AVG Volume (30 Days)
- VRCA 416.0K
- CTSO 497.4K
- Earning Date
- VRCA 02-27-2025
- CTSO 03-06-2025
- Dividend Yield
- VRCA N/A
- CTSO N/A
- EPS Growth
- VRCA N/A
- CTSO N/A
- EPS
- VRCA N/A
- CTSO N/A
- Revenue
- VRCA $9,210,000.00
- CTSO $37,739,531.00
- Revenue This Year
- VRCA $64.32
- CTSO $9.20
- Revenue Next Year
- VRCA $73.76
- CTSO $11.64
- P/E Ratio
- VRCA N/A
- CTSO N/A
- Revenue Growth
- VRCA 187.45
- CTSO 1.80
- 52 Week Low
- VRCA $0.61
- CTSO $0.70
- 52 Week High
- VRCA $11.41
- CTSO $1.59
- Technical
- Relative Strength Index (RSI)
- VRCA 46.69
- CTSO 49.90
- Support Level
- VRCA $0.68
- CTSO $0.98
- Resistance Level
- VRCA $0.75
- CTSO $1.07
- Average True Range (ATR)
- VRCA 0.06
- CTSO 0.07
- MACD
- VRCA 0.02
- CTSO -0.01
- Stochastic Oscillator
- VRCA 75.35
- CTSO 31.53
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.